MedTrace Logo

Antibody Responses to Pneumococcal Vaccines Among HIV-Infected Adults.

NCT00148824 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 212

Last updated 2008-03-21

No results posted yet for this study

Summary

Streptococcus pneumoniae is the major cause of bacterial infection in HIV-infected patients. The current pneumococcal vaccine is poorly efficacious in patients with a CD4 cell count lower than 500/mm3. This study will test the efficacy and safety of a new pneumococcal vaccine strategy in patients with a CD4 cell count between 200 and 500/mm3.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

7-valent pneumococcal conjugate vaccine (vaccine)

BIOLOGICAL

23-valent pneumococcal conjugate vaccine (vaccine)

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • French National Agency for Research on AIDS and Viral Hepatitis

    lead OTHER_GOV

Principal Investigators

  • Philippe Lesprit, MD · Service d'Immunologie Clinique, Créteil, 94010, France

  • Geneviève Chêne, MD, PhD · INSERM unité 593

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Completion
2006-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00148824 on ClinicalTrials.gov